PDCD1 and non-small cell lung carcinoma: In the experiments in vivo, JDB153 in combination with PD‐1 Ab or cisplatin exhibits synergetic antitumor capacity with good tolerance, which would be complementary to current antitumor approaches and aid the optimization of NSCLC treatment.